Xenon Pharmaceuticals(XENE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XENE Xenon Pharmaceuticals

Trading 06-24 10:01:53 EDT

55.60

+0.99

+1.81%

High55.69	Low54.61	Vol90.52K
Open54.61	D1 Closing54.61	Amplitude1.98%
Mkt Cap5.37B	Tradable Cap5.00B	Total Shares96.64M
T/O5.00M	T/O Rate0.10%	Tradable Shares89.89M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XENE","market":"US","secType":"STK","nameCN":"Xenon Pharmaceuticals","latestPrice":55.6,"timestamp":1782309709219,"preClose":54.61,"halted":0,"volume":90516,"delay":0,"changeRate":0.018128547885002785,"floatShares":89889500,"shares":96642822,"eps":-4.706128,"marketStatus":"Trading","change":0.99,"latestTime":"06-24 10:01:53 EDT","open":54.61,"high":55.69,"low":54.61,"amount":5002795.152228001,"amplitude":0.019777,"askPrice":55.7,"askSize":233,"bidPrice":55.5,"bidSize":123,"shortable":3,"etf":0,"ttmEps":-4.706128,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1782331200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1415163600000,"exchange":"NASDAQ","adjPreClose":54.61,"preHourTrading":{"tag":"盘前","latestPrice":54.7,"preClose":54.61,"latestTime":"09:29 EDT","volume":238,"amount":13023.099628,"timestamp":1782307799999,"change":0.09,"changeRate":0.001648,"amplitude":0.002747},"postHourTrading":{"tag":"盘后","latestPrice":54.61,"preClose":54.61,"latestTime":"17:25 EDT","volume":26278,"amount":1435025.74,"timestamp":1782249923149,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.771698,"impliedVol":0.4566,"impliedVolPercentile":0.4582},"requestUrl":"/m/hq/s/XENE/tweets","defaultTab":"tweets","newsList":[{"id":"2640189052","title":"Xenon shareholders approve 2026 equity incentive plan at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2640189052","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640189052?lang=en_us&edition=fundamental","pubTime":"2026-06-04 04:03","pubTimestamp":1780517009,"startTime":"0","endTime":"0","summary":"At a June 2, 2026 annual meeting, shareholders adopted Xenon’s 2026 Equity Incentive Plan, replacing the 2014 equity plan.Shareholders backed an annual advisory vote on executive pay.Shareholders also authorized the audit committee to set the auditor’s remuneration for the coming year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL59Zqtg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639672437","title":"BRIEF-Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2639672437","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639672437?lang=en_us&edition=fundamental","pubTime":"2026-05-30 04:01","pubTimestamp":1780084918,"startTime":"0","endTime":"0","summary":"BRIEF-Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing RuleMay 29 (Reuters) - Xenon Pharmaceuticals Inc XENE.O:XENON PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nTUABYY4TG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639672453","title":"Xenon Pharma grants 32,750 inducement stock options priced at $54.79 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2639672453","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639672453?lang=en_us&edition=fundamental","pubTime":"2026-05-30 04:01","pubTimestamp":1780084881,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals granted equity inducement awards to 10 new non-officer employees, totaling 32,750 share options, 19,200 RSUs.Options carry a $54.79 exercise price, matching the May 28, 2026 close; each option has a 10-year term.Options vest over four years: 25% after year one, then monthly for the remaining 36 months, subject to continued service.RSUs vest 25% on each of the first four anniversaries of the employee’s start date, subject to continued service.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDLbBf0HT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BGHQF748.EUR","BK4139","SG9999014021.USD","XENE","LU2210150020.SGD","SG9999014039.USD","IE00BN0W2T93.GBP","LU0314104364.USD","NDAQ","BK4112","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639672176","title":"Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2639672176","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639672176?lang=en_us&edition=fundamental","pubTime":"2026-05-30 04:01","pubTimestamp":1780084860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nTUABYY4TG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638686808","title":"Xenon Pharmaceuticals Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2638686808","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638686808?lang=en_us&edition=fundamental","pubTime":"2026-05-27 22:01","pubTimestamp":1779890460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XENE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 27, 2026 10:01 ET (14:01 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638688575","title":"Xenon Pharmaceuticals price target raised to $82 from $80 at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2638688575","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638688575?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:35","pubTimestamp":1779885312,"startTime":"0","endTime":"0","summary":"JPMorgan raised the firm’s price target on Xenon Pharmaceuticals (XENE) to $82 from $80 and keeps a Neutral rating on the shares. The firm updated ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xenon-pharmaceuticals-price-target-raised-to-82-from-80-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xenon-pharmaceuticals-price-target-raised-to-82-from-80-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PGF","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636281833","title":"Xenon Pharmaceuticals Signals Strong Momentum In Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2636281833","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636281833?lang=en_us&edition=fundamental","pubTime":"2026-05-20 13:05","pubTimestamp":1779253557,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals (($XENE)) has held its Q1 earnings call. Read on for the main highlights of the call. Xenon Pharmaceuticals’ latest earnings ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/xenon-pharmaceuticals-signals-strong-momentum-in-earnings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/xenon-pharmaceuticals-signals-strong-momentum-in-earnings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635379964","title":"A Look At Xenon Pharmaceuticals (XENE) Valuation After Phase III Azetukalner Milestones And Extended Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2635379964","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635379964?lang=en_us&edition=fundamental","pubTime":"2026-05-14 14:50","pubTimestamp":1778741421,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals (XENE) stock is in focus after the company paired encouraging Phase III azetukalner epilepsy data with plans for a Q3 2026 NDA filing and a defined commercial launch timeline.\nSee our latest analysis for Xenon Pharmaceuticals.\nDespite a softer 7 day and 30 day share price return, Xenon’s recent Phase III update and extended cash runway have come after a 34.26% 90 day share price return and a very strong 1 year total shareholder return of 87.9%. This suggests that...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/a-look-at-xenon-pharmaceuticals-xene-valuation-after-phase-i","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/a-look-at-xenon-pharmaceuticals-xene-valuation-after-phase-i","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","XENE","BK4134","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634106243","title":"Xenon Pharmaceuticals Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2634106243","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634106243?lang=en_us&edition=fundamental","pubTime":"2026-05-12 23:23","pubTimestamp":1778599380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XENE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 12, 2026 11:23 ET (15:23 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634404219","title":"Xenon Pharmaceuticals price target raised to $80 from $77 at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2634404219","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634404219?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:13","pubTimestamp":1778588036,"startTime":"0","endTime":"0","summary":"JPMorgan analyst Tessa Romero raised the firm’s price target on Xenon Pharmaceuticals (XENE) to $80 from $77 and keeps an Overweight rating on the ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xenon-pharmaceuticals-price-target-raised-to-80-from-77-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xenon-pharmaceuticals-price-target-raised-to-80-from-77-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PGF","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634475369","title":"Xenon (XENE) Gets a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2634475369","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634475369?lang=en_us&edition=fundamental","pubTime":"2026-05-11 10:40","pubTimestamp":1778467236,"startTime":"0","endTime":"0","summary":"In a report released on May 8, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Xenon, with a price target of $86.00. The company’s sha...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/xenon-xene-gets-a-buy-from-stifel-nicolaus-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/xenon-xene-gets-a-buy-from-stifel-nicolaus-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","BK4139","BK4127","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634428805","title":"Xenon Pharmaceuticals price target raised to $69 from $68 at Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2634428805","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634428805?lang=en_us&edition=fundamental","pubTime":"2026-05-10 22:21","pubTimestamp":1778422888,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Benjamin Burnett raised the firm’s price target on Xenon Pharmaceuticals (XENE) to $69 from $68 and keeps an Overweight rating ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xenon-pharmaceuticals-price-target-raised-to-69-from-68-at-wells-fargo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xenon-pharmaceuticals-price-target-raised-to-69-from-68-at-wells-fargo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PGF","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634966440","title":"Wells Fargo Remains a Buy on Xenon (XENE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634966440","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634966440?lang=en_us&edition=fundamental","pubTime":"2026-05-10 21:40","pubTimestamp":1778420417,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Benjamin Burnett maintained a Buy rating on Xenon on May 8 and set a price target of $69.00. The company’s shares closed last F...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-remains-a-buy-on-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-remains-a-buy-on-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0130102774.USD","IE000M9KFDE8.USD","LU1035773651.USD","LU2361045086.USD","LU0072461881.USD","LU2361044949.HKD","IE00B19Z3581.USD","LU0787776722.HKD","LU0868494708.USD","LU1814569148.SGD","BK4582","LU0128525929.USD","BK4559","LU0640476718.USD","LU0417517546.SGD","LU0971096721.USD","LU0070302665.USD","LU1894683348.USD","LU0310800965.SGD","LU1668664300.SGD","LU0128525689.USD","LU0314106906.USD","LU0980610538.SGD","LU1267930490.SGD","LU1074936037.SGD","LU0289960550.SGD","LU0477156953.USD","LU0154236417.USD","LU0211328371.USD","PGF","LU1267930227.SGD","LU0742534661.SGD","LU0648001328.SGD","LU0106831901.USD","XENE","BK4585","BK4504","BK4207","LU0175139822.USD","LU0683600562.USD","LU1267930573.SGD","LU0208291251.USD","IE00B7SZLL34.SGD","LU2236285917.USD","LU0310800379.SGD","LU1069347547.HKD","LU0251142724.SGD","LU1506573853.SGD","LU0048573561.USD","LU1363072403.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634849830","title":"Xenon Pharmaceuticals price target lowered to $78 from $80 at Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2634849830","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634849830?lang=en_us&edition=fundamental","pubTime":"2026-05-09 06:33","pubTimestamp":1778279604,"startTime":"0","endTime":"0","summary":"Needham analyst Serge Belanger lowered the firm’s price target on Xenon Pharmaceuticals (XENE) to $78 from $80 and keeps a Buy rating on the shares...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xenon-pharmaceuticals-price-target-lowered-to-78-from-80-at-needham-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xenon-pharmaceuticals-price-target-lowered-to-78-from-80-at-needham-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633453003","title":"Xenon Pharmaceuticals Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2633453003","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633453003?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:46","pubTimestamp":1778240760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XENE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2026 07:46 ET (11:46 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633532344","title":"Needham Reaffirms Their Buy Rating on Xenon (XENE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633532344","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633532344?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:35","pubTimestamp":1778240134,"startTime":"0","endTime":"0","summary":"Needham analyst Serge Belanger maintained a Buy rating on Xenon today and set a price target of $78.00. According to TipRanks, Belanger is a 5-star...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/needham-reaffirms-their-buy-rating-on-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/needham-reaffirms-their-buy-rating-on-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633194430","title":"H.C. Wainwright Remains a Buy on Xenon (XENE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633194430","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633194430?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:55","pubTimestamp":1778237748,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Xenon today and set a price target of $74.00. Tsao covers the Healthcare sector, fo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","XENE","XBI","BK4139","BK4581","XLV","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633865108","title":"Xenon Pharmaceuticals Q1 Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2633865108","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633865108?lang=en_us&edition=fundamental","pubTime":"2026-05-08 05:28","pubTimestamp":1778189283,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals (XENE) reported late Thursday a Q1 net loss of $1.17 per diluted share, compared with a loss of $0.83 a year earlier.Based on current operating plans, Xenon said it expects having sufficient cash to fund operations into 2029.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633332170","title":"Earnings Flash (XENE) Xenon Pharmaceuticals Posts Q1 Per Share Loss $1.17, vs. FactSet Est of Loss $1.18","url":"https://stock-news.laohu8.com/highlight/detail?id=2633332170","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633332170?lang=en_us&edition=fundamental","pubTime":"2026-05-08 05:05","pubTimestamp":1778187923,"startTime":"0","endTime":"0","summary":"Earnings Flash (XENE) Xenon Pharmaceuticals Posts Q1 Per Share Loss $1.17, vs. FactSet Est of Loss $1.18","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633779031","title":"Xenon Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633779031","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633779031?lang=en_us&edition=fundamental","pubTime":"2026-05-08 05:01","pubTimestamp":1778187681,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings SummaryXenon Pharmaceuticals Inc XENE.OQ reported a quarterly adjusted loss of $1.17 per share for the quarter ended","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL8N41K3A4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xenon-pharma.com;investor.xenon-pharma.com","stockEarnings":[{"period":"1week","weight":0.0504},{"period":"1month","weight":0.0081},{"period":"3month","weight":-0.0173},{"period":"6month","weight":0.2133},{"period":"1year","weight":0.7342},{"period":"ytd","weight":0.2184}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0162},{"period":"3month","weight":0.1169},{"period":"6month","weight":0.0626},{"period":"1year","weight":0.2223},{"period":"ytd","weight":0.0758}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.008322},{"month":2,"riseRate":0.75,"avgChangeRate":0.076063},{"month":3,"riseRate":0.25,"avgChangeRate":-0.040327},{"month":4,"riseRate":0.5,"avgChangeRate":0.017963},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.036246},{"month":6,"riseRate":0.416667,"avgChangeRate":0.029418},{"month":7,"riseRate":0.363636,"avgChangeRate":0.01913},{"month":8,"riseRate":0.727273,"avgChangeRate":0.07504},{"month":9,"riseRate":0.181818,"avgChangeRate":-0.05886},{"month":10,"riseRate":0.454545,"avgChangeRate":0.054946},{"month":11,"riseRate":0.727273,"avgChangeRate":0.050412},{"month":12,"riseRate":0.666667,"avgChangeRate":0.089745}],"exchange":"NASDAQ","name":"Xenon Pharmaceuticals","nameEN":"Xenon Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xenon Pharmaceuticals(XENE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Xenon Pharmaceuticals(XENE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Xenon Pharmaceuticals,XENE,Xenon Pharmaceuticals股票,Xenon Pharmaceuticals股票老虎,Xenon Pharmaceuticals股票老虎国际,Xenon Pharmaceuticals行情,Xenon Pharmaceuticals股票行情,Xenon Pharmaceuticals股价,Xenon Pharmaceuticals股市,Xenon Pharmaceuticals股票价格,Xenon Pharmaceuticals股票交易,Xenon Pharmaceuticals股票购买,Xenon Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xenon Pharmaceuticals(XENE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Xenon Pharmaceuticals(XENE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction